JPMorgan Chase & Co. Invests $517,000 in Cellectis SA (CLLS) Stock

JPMorgan Chase & Co. bought a new position in shares of Cellectis SA (NASDAQ:CLLS) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 18,810 shares of the biotechnology company’s stock, valued at approximately $517,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its stake in Cellectis by 79.1% during the 2nd quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares in the last quarter. Williams Jones & Associates LLC acquired a new position in Cellectis during the 2nd quarter worth $244,000. Wells Fargo & Company MN grew its stake in Cellectis by 132.1% during the 2nd quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares in the last quarter. Advisors Asset Management Inc. grew its stake in Cellectis by 1,501.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock worth $643,000 after purchasing an additional 21,181 shares in the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Cellectis during the 2nd quarter worth $719,000. 16.35% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently commented on CLLS. BidaskClub cut Cellectis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Jefferies Group reaffirmed a “buy” rating and set a $47.00 price objective on shares of Cellectis in a research report on Tuesday, September 26th. SunTrust Banks reaffirmed a “hold” rating and set a $20.00 price objective on shares of Cellectis in a research report on Friday, October 6th. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research report on Thursday, December 28th. Finally, ValuEngine cut Cellectis from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $39.29.

Cellectis SA (NASDAQ CLLS) opened at $27.78 on Wednesday. The stock has a market capitalization of $990.86 and a PE ratio of -9.99. Cellectis SA has a 1 year low of $17.25 and a 1 year high of $35.07.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.16). Cellectis had a negative return on equity of 30.66% and a negative net margin of 217.25%. research analysts predict that Cellectis SA will post -2.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.com-unik.info/2018/01/17/jpmorgan-chase-co-invests-517000-in-cellectis-sa-clls-stock.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).

Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit